Xbiotech, which is developing antibodies for colorectal cancer and various other conditions, raised $76 million by offering 4 million shares at $19, within the range of $18 to $20. The IPO was being marketed by WR Hambrecht on a "best efforts"...read more
Xbiotech, which is developing antibodies for colorectal cancer and various other conditions, announced terms for its IPO on Tuesday. The IPO is being marketed by WR Hambrecht on a "best efforts" basis. The Austin, TX-based company plans to raise $76...read more
Alder BioPharmaceuticals, which is developing antibodies to prevent migraine and treat rheumatoid arthritis, raised $80 million by offering 8.0 million shares at $10, below its proposed $13 to $15 range. Alder BioPharmaceuticals will list on the NASDAQ under the...read more
Colorectal cancer biotech Xbiotech prices $76 million IPO at $19 midpoint
Xbiotech, which is developing antibodies for colorectal cancer and various other conditions, raised $76 million by offering 4 million shares at $19, within the range of $18 to $20. The IPO was being marketed by WR Hambrecht on a "best efforts"...read more
Anitbody biotech Xbiotech sets terms for $76 million IPO
Xbiotech, which is developing antibodies for colorectal cancer and various other conditions, announced terms for its IPO on Tuesday. The IPO is being marketed by WR Hambrecht on a "best efforts" basis. The Austin, TX-based company plans to raise $76...read more
Alder BioPharmaceuticals prices upsized IPO at $10, well below the range
Alder BioPharmaceuticals, which is developing antibodies to prevent migraine and treat rheumatoid arthritis, raised $80 million by offering 8.0 million shares at $10, below its proposed $13 to $15 range. Alder BioPharmaceuticals will list on the NASDAQ under the...read more
9 US IPOs planned for the week of May 5
The following IPOs are expected to price this week: Alder BioPharmaceuticals (ALDR), which is developing antibodies for rheumatoid arthritis with Bristol-Myers and...read more